Planmeca USA v. Osseo Imaging — Federal Circuit Affirms 3D Imaging Patents
Planmeca USA challenged Osseo Imaging over three dental cone-beam CT patents covering ProMax 3D imaging systems. The Federal Circuit affirmed the lower court’s decision on 4 September 2024, closing the 533-day appeal without reversible error and leaving Osseo’s patent portfolio intact.
Federal Circuit closes ProMax 3D imaging dispute after 533-day appeal
Planmeca USA, Inc. filed this appeal at the United States Court of Appeals for the Federal Circuit on 21 March 2023, targeting Osseo Imaging, LLC’s enforcement of three patents — US6381301B1, US6944262B2, and US8498374B2 — each directed at cone-beam 3D dental imaging technology commercialised through the ProMax 3D imaging platform. The underlying action was characterised as an infringement action, placing the validity and scope of Osseo’s imaging patents at the centre of the dispute.
The Federal Circuit issued its order on 4 September 2024, affirming the decision below in full. An affirmance at this level means the appellate panel identified no reversible legal error in the lower tribunal’s reasoning, leaving the original outcome — and Osseo’s patent rights — undisturbed. The basis of termination is recorded as ‘Appeal Dismissed,’ which, read alongside the explicit ‘AFFIRMED’ verdict, suggests the affirmance effectively closed the appellate proceeding without remand.
The 533-day duration from filing to closure is consistent with a substantive Federal Circuit review rather than a procedural dismissal, suggesting the panel engaged with the merits. What specific claim construction, validity, or infringement arguments were raised and how the panel weighted each finding is not fully disclosed in the public record. The outcome strengthens the enforceability signal for Osseo’s three patents and raises the bar for any future challenge to the ProMax 3D imaging claims.
Filing to Appeal Dismissed in 533 days
533 days at the Federal Circuit — longer than the median CAFC appeal (~400 days)
Federal Circuit affirms: what the ruling means for both parties
What ‘AFFIRMED’ means at the Federal Circuit
An affirmance from the Federal Circuit means the appellate panel reviewed the lower court’s findings — on claim construction, validity, and/or infringement — and identified no reversible error. The original decision stands in full. The Federal Circuit applies a de novo standard to legal questions such as claim construction and a clear-error standard to factual findings, making an affirmance a meaningful endorsement of the reasoning below.
No reversible error foundOsseo’s three imaging patents emerge reinforced
For Osseo Imaging, the affirmance preserves the enforceability of all three patents — US6381301B1, US6944262B2, and US8498374B2 — covering ProMax 3D cone-beam imaging. A Federal Circuit affirmance signals that the claim scope and any validity findings survived appellate scrutiny, strengthening Osseo’s position in any future licensing discussions or parallel enforcement actions against other dental imaging manufacturers.
Patents survive appealPlanmeca’s appellate options are effectively exhausted
Planmeca USA’s affirmance leaves it with limited further options at this level. A petition for rehearing en banc or a certiorari petition to the Supreme Court are theoretically available but rarely granted. Absent a successful inter partes review or post-grant challenge through the USPTO, Planmeca faces the affirmed lower court outcome with no practical appellate path remaining. The cost of continued challenge now rises significantly.
Appellate path largely closedHigher enforcement risk for 3D dental imaging competitors
The affirmance strengthens Osseo’s leverage across the dental cone-beam CT sector. Competitors and OEMs whose products share architectural similarities with the ProMax 3D platform should reassess their freedom-to-operate posture against all three patents. A Federal Circuit-affirmed patent presents a higher bar for invalidity arguments and a more credible threat in licensing negotiations, potentially accelerating royalty demands across the dental imaging supply chain.
Elevated FTO risk for sectorFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Planmeca USA, Inc. | Company | Appellant dental imaging company — challenged Osseo’s ProMax 3D cone-beam CT patentsSearch in Eureka ↗ |
| Defendant | Osseo Imaging, LLC | Company | Osseo Imaging, LLC — holder of US6381301B1, US6944262B2 and US8498374B2 covering 3D dental imagingSearch in Eureka ↗ |
| Plaintiff counsel | Blake Dietrich | Attorney | Counsel for Planmeca USA, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Leisa Talbert Peschel | Attorney | Counsel for Planmeca USA, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael J. Flynn | Attorney | Counsel for Planmeca USA, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Wasif Qureshi | Attorney | Counsel for Planmeca USA, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Jackson Walker LLP | Law Firm | Representing Planmeca USA, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Planmeca USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Robert Feinland | Attorney | Counsel for Osseo Imaging, LLCSearch in Eureka ↗ |
| Defendant counsel | Seth Ostrow | Attorney | Counsel for Osseo Imaging, LLCSearch in Eureka ↗ |
| Defendant law firm | Meister Seelig & Fein, PLLC | Law Firm | Representing Osseo Imaging, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s terse order — ‘ORDERED AND ADJUDGED: AFFIRMED’ — is consistent with a Rule 36 summary affirmance, which the court issues when the lower tribunal’s decision is considered correct and no further written opinion is needed. While brief, the order carries full precedential weight as an affirmance on the merits. For Osseo, it means the infringement and/or validity findings are judicially confirmed. For Planmeca, no remand or further proceeding was directed, effectively closing the appellate chapter.
US6381301B1, US6944262B2 & US8498374B2 — ProMax 3D Cone-Beam Dental Imaging
The three patents at issue — US6381301B1 (application US09/452348), US6944262B2 (application US10/351567), and US8498374B2 (application US13/619356) — span a generational arc of cone-beam CT technology applied to dental and maxillofacial imaging. Filed across distinct periods, they collectively cover hardware architecture, image reconstruction methodology, and processing refinements central to 3D intraoral and craniofacial diagnostic platforms such as the ProMax 3D. Cone-beam CT patents in this segment typically protect the geometry of X-ray source-detector rotation, volumetric reconstruction algorithms, and dose-management features.
Strategically, a portfolio of three temporally staggered cone-beam CT patents creates layered exclusivity: early patents covering core system architecture are complemented by continuation or improvement patents covering software and processing refinements, making design-around difficult without addressing all three claim families. The Federal Circuit affirmance signals that this layered strategy survived litigation, increasing Osseo’s leverage against any dental imaging manufacturer whose platform relies on similar cone-beam acquisition and reconstruction principles — including both domestic and internationally marketed CBCT units.
Should you run an FTO analysis against US6381301B1, US6944262B2 & US8498374B2?
Any company developing, manufacturing, or distributing cone-beam CT dental imaging systems — including CBCT hardware, reconstruction software, or integrated diagnostic platforms — should treat these three Osseo patents as active FTO risk factors following the Federal Circuit affirmance. Product teams working on detector array configurations, volumetric reconstruction pipelines, or dose optimisation modules in dental imaging devices are particularly exposed. The affirmed claim scope is now litigation-hardened, meaning an FTO gap could translate directly into injunctive risk or a royalty demand backed by a Federal Circuit win.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the claim trees of all three Osseo patents simultaneously, flagging overlapping claim language and identifying prosecution history estoppel that may limit or expand enforcement reach. Eureka’s citation graph also surfaces prior art that was not raised in the Planmeca litigation — critical intelligence if you are evaluating an IPR petition or building a design-around strategy. Run your FTO before your next product development milestone, not after a cease-and-desist letter.
Run a freedom-to-operate analysis on US6381301B1 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in dental and medical 3D imaging patents
Cases involving cone-beam CT and 3D dental imaging patents at the Federal Circuit offer direct benchmarks for claim construction risk and affirmance rates in this technology sector.
What this case signals for the dental 3D imaging IP landscape
A Federal Circuit affirmance on three cone-beam CT patents reshapes the competitive and licensing environment for dental imaging manufacturers.
Federal Circuit affirmance raises the invalidity bar for all three patents
Having survived both the lower court and appellate review, US6381301B1, US6944262B2, and US8498374B2 now carry a stronger presumption of validity. Any party seeking to design around or challenge these patents must contend with findings that withstood Federal Circuit scrutiny — typically the highest bar short of Supreme Court review in US patent law.
IPR or post-grant proceedings may be Planmeca’s only remaining path
With direct appellate challenge exhausted, inter partes review at the USPTO represents the most viable route to invalidate Osseo’s claims. However, IPR estoppel rules mean Planmeca must carefully assess which prior art grounds were raised in litigation to avoid being barred from raising them again — a strategic consideration that requires immediate attention post-affirmance.
Planmeca v Osseo — key questions answered
The Federal Circuit affirmed the lower court’s decision in full on 4 September 2024. The order — ‘ORDERED AND ADJUDGED: AFFIRMED’ — confirms that no reversible error was found in the proceedings below concerning Osseo Imaging’s three dental cone-beam CT patents: US6381301B1, US6944262B2, and US8498374B2.
Three patents were involved: US6381301B1, US6944262B2, and US8498374B2. All relate to cone-beam 3D dental imaging technology associated with the ProMax 3D imaging platform. The Federal Circuit’s affirmance leaves all three patents enforceable with the claim scope determined by the lower court.
The affirmance strengthens Osseo’s enforcement position considerably. All three patents now carry findings that survived both the lower court and appellate review, making invalidity arguments harder to sustain. Osseo can use the Federal Circuit-backed outcome to support licensing demands or future infringement actions against other dental imaging manufacturers.
Planmeca’s options are limited. It could petition for rehearing en banc at the Federal Circuit or seek certiorari from the Supreme Court, both of which are rarely granted. Alternatively, it could file inter partes review petitions at the USPTO targeting the three patents, though IPR estoppel rules may restrict which prior art grounds are available depending on what was raised in the district court litigation.
Federal Circuit Rule 36 allows the court to affirm a lower court decision without a written opinion when the panel agrees the decision is correct. The brief order language in case 23-1627 — with no published opinion referenced — is consistent with a Rule 36 summary affirmance, though the public record does not explicitly confirm this. Such affirmances carry full legal weight but provide no additional claim construction guidance for third parties.
PatSnap Eureka searches patents and litigation data to answer instantly.